mannose phosphate isomerase mpi deficiency market size
DelveInsight's "Mannose Phosphate Isomerase (MPI) Deficiency - Market Insights, Epidemiology and Market Forecast-2028" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of MPI in the United States and EU5 (Germany, Spain, Italy, France and United Kingdom).
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Mannose Phosphate Isomerase (MPI) deficiency from 2016 to 2028 segmented by six major markets. The Report also covers current treatment practice, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2016-2028
Mannose Phosphate Isomerase (MPI) Deficiency - Disease Understanding and Treatment Algorithm
The DelveInsight Mannose Phosphate Isomerase (MPI) Deficiency market report gives the thorough understanding of the Mannose Phosphate Isomerase (MPI) Deficiency by including details such as disease definition, causes, symptoms, pathophysiology, and diagnostic trends. It also provides overview of treatment and management of the disease in the US and EU5.
Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology
The Mannose Phosphate Isomerase (MPI) Deficiency epidemiology division provide the insights about historical and current patient pool and forecasted trend for every six major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and the prevalence based on clinical manifestations in the US and EU5.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed prevalent cases, and prevalence based on clinical manifestations) scenario of Mannose Phosphate Isomerase (MPI) Deficiency in the 6MM covering United States and EU5 countries (Germany, Spain, Italy, France and United Kingdom) from 2016-2028.
According to DelveInsight, total prevalent population of Mannose Phosphate Isomerase (MPI) Deficiency in six major markets was found to be 84 in 2016.?
Mannose Phosphate Isomerase (MPI) Deficiency Drug Chapters
This segment of the MPI Drug report encloses the detailed analysis of the emerging drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, and the latest news and press releases.
At present, therapeutic approach of MPI involves substrate replacement therapy i.e. the D-Mannose therapy. D-Mannose therapy has shown improvement in all major symptoms associated with the disease, but no benefits in liver conditions such as fibrosis and cirrhosis. Liver transplantation is the only resolution to control liver conditions associated with this disorder. Till date no drug has obtained approval for the treatment of MPI deficiency. Detailed chapter for upcoming therapies like ORL-1M (Orpha Labs), and other promising therapies such as CERC-802 (Cerecor Inc.) have been covered in the report.
Mannose Phosphate Isomerase (MPI) Deficiency Market Outlook
The MPI market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers.
This segment gives a through detail of emerging therapies and other promising therapies by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Mannose Phosphate Isomerase (MPI) Deficiency in 6MM was found to be USD 0.61 Million in 2016.
Mannose Phosphate Isomerase (MPI) Deficiency Drugs Uptake
This section focusses on the rate of uptake of the potential drugs that will get launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Mannose Phosphate Isomerase (MPI) Deficiency Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Mannose Phosphate Isomerase (MPI) Deficiency Report Key Strengths
• 10 Year Forecast
• 6MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Market Size by Therapies
• Key Cross Competition
Mannose Phosphate Isomerase (MPI) Deficiency Report Assessment
• Pipeline Product Profiles
• Key Products and Key Players
• Market Drivers and Barriers
Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Mannose Phosphate Isomerase (MPI) Deficiency market.
• Organize sales and marketing efforts by identifying the best opportunities for Idiopathic Pulmonary Fibrosis market.
• To understand the future market competition in the Mannose Phosphate Isomerase (MPI) Deficiency market.
